As BMP6 upregulation has also been shown to mediate onset and progression of cerebral cavernous malformations by inducing BMP and TGFβ-signaling [11], Hippo pathway inhibitors may act as potential molecular targets for this disease. This evidence concerns the gene TGFB1 and famililal cerebral cavernous malformations.